ARMATA PHARMACEUTICALS ARMP 深 沪
等待开盘 12-17 09:30:00 美东时间
5.72
-0.440
-7.14%
华盛通- 最 高6.29
- 今 开6.21
- 成交量 3.29万股
- 最 低 5.52
- 昨 收 6.16
- 总市值 2.08亿
- 52周最高 16.34
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 0.8981
- 委 比 0.00%
- 总股本 3632.98万
- 历史最高 16.34
- 量 比 1.02
- 振 幅 12.50%
- 历史最低 0.8311
- 每 手 1
- 风险率 1.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Armata Pharmaceuticals Q3 EPS $(0.74) Misses $(0.42) Estimate, Sales $1.159M Miss $1.380M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.42) by 76.19 percent. This is a 393.33 percent decrease over losses of $(0.15) per
11-13 05:40
Armata Pharmaceuticals Commissions Good Manufacturing Practice Production Facility In Los Angeles
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the
11-10 20:07
美股牛股 | ARMP大涨超103%！抗血感染药物在中期试验中显示出积极结果；直觉外科公司涨近14%
ARMP大涨超103%！抗血感染药物在中期试验中显示出积极结果；直觉外科公司涨近14%，Q3业绩表现优异，远超市场预期>>
10-23 14:51
Here’s Why Armata Pharmaceuticals Stock (ARMP) Exploded 300% Today
Armata Pharmaceuticals ($ARMP) stock exploded nearly 300% on Wednesday after th...
10-23 03:53
Armata Pharma Reports Results From Its Recently Completed Phase 2a diSArm Study Of AP-SA02 As A Potential Treatment For Complicated Staphylococcus Aureus Bacteremia In A Late-Breaking Oral Presentation At IDWeek 2025
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of
10-22 23:12
Armata Pharmaceuticals Advances Cystic Fibrosis Infection Treatment With Phage Research
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of
09-08 19:11
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02 LOS ANGELES, Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceutica...
09-08 19:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Armata Pharmaceuticals Files For Mixed Shelf Of Up To $100M
https://www.sec.gov/Archives/edgar/data/921114/000110465925077648/tm2523066d1_s3.htm
08-14 05:20
Armata Pharmaceuticals Q2 EPS $(0.45) Misses $(0.39) Estimate, Sales $2.169M Beat $1.380M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 80 percent decrease over losses of $(0.25) per share
08-13 04:32
